BioPharmSignal logoBioPharmSignal

Biotech News

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Intensity Therapeutics (INTS)Intensity TherapeuticsEarnings

INTS (INTS) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ints.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

INTSIntensity Therapeutics2026-08-04 12:00 EST

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

View all latest news

Intensity Therapeutics

Intratumoral Cancer Therapy Intensity Therapeutics develops medicines administered directly into tumors. Its approach is designed to kill injected tumor cells, expose tumor antigens and stimulate a broader immune response. INT230-6 INT230-6 combines cytotoxic agents with a proprietary dispersion molecule intended to improve penetration...

Recent company news

INTSIntensity Therapeutics2026-08-04 12:00 EST

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

INTSIntensity Therapeutics2026-07-15 11:45 EST

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

INTSIntensity Therapeutics2026-07-01 12:00 EST

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

INTSIntensity Therapeutics2026-05-14 12:00 EST

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

INTSIntensity Therapeutics2026-05-07 20:06 EST

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
4.25 USD
Market cap
11.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States